-
Andorra's third-generation oral breast cancer Class 1 new drug was approved for clinical use in the U.S.
Time of Update: 2021-10-22
On October 1, the third-generation oral breast cancer class 1 new drug AND019 independently developed by Andorra Pharmaceuticals obtained clinical approval from the US FDA .
-
National Food and Drug Administration: Conversion of Aloe Pearl Capsules from Prescription Drugs to Over-the-Counter Drugs
Time of Update: 2021-10-22
Variety of over-the-counter drug instructions templateAloe Pearl Capsule InstructionsPlease read the instructions carefully and use according to the instructions or purchase and use under the guidance of a pharmacist[Drug Name]Generic name: aloe pearl capsulesChinese Pinyin:[Ingredients][Properties][Functions and Indications] Clearing heat and leading to stagnation, promoting qi and defecation .
-
Drug Administration: Kangye Medical Devices and Zhongyi Technology are recalling a batch of medical devices
Time of Update: 2021-10-22
On September 27, the State Food and Drug Administration issued an announcement to notify Kangye Medical Devices and Zhongyi Technology of the voluntary recall of some of its products in violation of regulations .
-
Bojian was sued by insurance company Humana for illegally promoting drug sales through charitable donations
Time of Update: 2021-10-22
Biogen is also one of the pharmaceutical companies that previously signed a settlement agreement with the US government, but now the medical insurance giant Humana is filing a new lawsuit against the company's illegal charitable donations .
-
A new target for tumor immunity!
Time of Update: 2021-10-22
Preclinical studies have shown that SIM0235 has high binding specificity, can effectively block the activation of NF-κB signaling pathway induced by the combination of tumor necrosis factor α (TNFα) and TNFR2, effectively inhibit the proliferation and function of Treg cells, and regulate the immune microenvironment .
-
Hengrui Medicine's 1.3 billion innovative drug Punaburin will be another wealth code?
Time of Update: 2021-10-22
Figure 2 The inhibitory activity of punabulin on tumor cell lines and drug-resistant tumor cell linesIn 2011, Professor Hayashi summarized the structure-activity relationship of punabrine modified by phenylahistin (see Figure 3): 1.
-
Luye Pharma's Class 1 new drug, a new generation of VMAT2 inhibitor LY03015, will soon enter the clinic in China
Time of Update: 2021-10-22
In addition to products already on the market, Luye Pharma has a number of new drugs under development that have entered the late-stage clinical and New Drug Application (NDA) stages in China, the United States and other markets, covering a variety of diseases such as depression and Parkinson's disease, forming in the central nervous system treatment field.
-
Ruike Biotechnology and Ruiji Biotechnology reached an mRNA vaccine cooperation agreement
Time of Update: 2021-10-22
The joint venture company will use mRNA technology and new adjuvant technology to develop a new generation of new crown vaccines, and plans to gradually expand to other major infectious disease vaccines and tumor therapeutic vaccines .
-
Unannounced inspections for drug retail companies Shunyi
Time of Update: 2021-10-22
Recently, the Shunyi District Market Supervision Administration continued to carry out unannounced inspections of pharmaceutical retail companies throughout the district, continuously strengthened the supervision of pharmaceutical retail companies, and urged pharmacies to play the role of "sentinel" to ensure the quality and safety of pharmaceutical equipment in the jurisdiction .
-
Centralized procurement to promote insulin and Chinese patent medicines to promote drug bidding in one place and publish new "retaliatory" regulations
Time of Update: 2021-10-22
Looking back at the first round of the first-round list of 20 key monitored drugs issued by the National Health and Medical Commission, they did not include proprietary Chinese medicines .
On September 25th, Hubei issued an announcement on the centralized procurement of the Inter-Provincial Volume Procurement Alliance of Chinese Patent Medicines .
-
Summary and outlook of the pharmaceutical equipment industry in the first three quarters of 2021
Time of Update: 2021-10-22
The industry believes that or indirectly brings development opportunities to the upstream pharmaceutical equipment industry; another example is Chinese medicine formula granules.
Favorable policy advancement, entering the fourth quarter, the pharmaceutical equipment industry is expected to continue its growth trend .
-
Amgen's lipid-lowering drug Repatha receives FDA approval to treat children with HeFH cholesterol disease
Time of Update: 2021-10-22
CompilationFan DongdongA few days ago, the FDA announced that it would approve the use of Amgen’s PCSK9 inhibitor Repatha as an additional treatment for dietary adjustments and statins for the treatment of pediatric patients 10 years of age and older with heterozygous familial hypercholesterolemia (HeFH).
-
1 missing!
Time of Update: 2021-10-22
Everyone should remember that on September 30th, on the eve of National Day, the Guangdong Provincial Drug Trading Center issued the "Guangdong Union Diclofenac and other 153 drug groups with a large amount of procurement documents (draft for comments)", covering three types of drugs including blood products and basic infusions.
153 varieties are procured in quantity.
-
Total failure!
Time of Update: 2021-10-22
Even so, the failure of the first mid-term ulcerative colitis study of deucravacitinib was undoubtedly a setback for Bristol-Myers Squibb's decision to uninstall the Otezla drug candidate .
-
Eisai China won the 2020 Economic Contribution Award-Outstanding Contribution Award for Output Efficiency
Time of Update: 2021-10-22
Suzhou, October 8, 2021/PRNewswire/ - On September 28, Eisai China won the 2020 Economic Contribution in the 2021 Suzhou Municipal Government’s exchange activities with multinational companies and the awarding ceremony of the honorary title of Suzhou’s foreigners Award-Outstanding Contribution Award for Output Benefits, in recognition of the remarkable, iconic and leading contribution to Suzhou's economic development .
-
Many places began to implement the fifth batch of national sourcing of medicines, and a new competition pattern in the pharmaceutical market is approaching
Time of Update: 2021-10-22
It is reported that the fifth batch of national procurement of medicines has a total of 61 products selected, with an average decrease of 56%; the varieties involve common diseases such as hypertension, diabetes, coronary heart disease, digestive tract diseases, and drugs for chronic diseases, as well as drugs for major diseases such as lung cancer and pancreatic cancer.
-
Hengrui wins the first review with 2 billion anesthetics
Time of Update: 2021-10-22
Author: Bai YuA few days ago, Hengrui Pharmaceuticals issued an announcement stating that the company has been approved for inhalation sevoflurane for imitation of the 4 types of applications and is deemed to have been reviewed.
-
With the continuous expansion of the market size of Chinese herbal medicine decoction pieces, ensuring high-quality development has become a top priority
Time of Update: 2021-10-22
. Industry analysis believes that, in fact, in recent years, market regulatory authorities in various regions have been constantly "strikes out", strengthened special rectification of traditional Chinese medicine decoction pieces, actively promoted standardized production, strengthened supervision of pesticide residues, and regulated the operation and use behavior of traditional Chinese medicine decoction pieces.
-
Weijian Pharmaceuticals and China Rare Disease Alliance strategically cooperate to help the construction of a healthy ecology for rare diseases
Time of Update: 2021-10-22
Boao, Hainan, October 8, 2021/PRNewswire/ - September 30, 2021 (Hainan·Boao), Hong Kong Weijian Pharmaceutical Group ("Vaijian Pharmaceutical") and China Rare Disease Alliance formally signed a five-y
-
Kangfang Biological Announces Phase II Data of PD-1/VEGF Double Antibody + Chemotherapy First-line Treatment of NSCLC
Time of Update: 2021-10-22
This multicenter, open phase II clinical study (AK112-201, NCT04736823) aims to evaluate the effectiveness and safety of AK112 combined with chemotherapy in the treatment of advanced non-small cell lung cancer .